Migraine is not just a bad headache. It can involve severe head pain, nausea, light sensitivity, sound sensitivity, visual symptoms, exhaustion and days of disrupted life. Other headache disorders, including cluster headache and chronic tension-type headache, can also be disabling. Patients are understandably curious about medical cannabis when standard treatments have not been enough.
The evidence boundary needs to be visible from the start: medical cannabis should not be presented as a proven migraine treatment. UK guidance does not recommend cannabis-based medicinal products as a routine headache or migraine treatment. NICE’s cannabis-based medicinal products guideline is restrictive for chronic pain, and NHS migraine guidance focuses on recognised acute and preventive treatments.
Private specialist assessment may still be discussed by some patients, but a diagnosis of migraine or headache disorder does not equal qualification. Any assessment depends on the exact headache diagnosis, previous treatments, current medicines, medication-overuse risk, mental health, impairment, records and specialist clinical judgement.
This article is not medical advice. It cannot decide whether any treatment is suitable for you, and it does not recommend a product, dose, route, clinic or pharmacy.
For wider access context, start with the MCPH patient guide. If pain guidance is part of your question, also read medical cannabis for chronic pain: what NICE says and medical cannabis and medication interactions.
The short answer
Migraine and headache disorders can be severe enough to justify specialist care, but the medical cannabis evidence is not strong enough for MCPH to call it a treatment option or imply expected benefit.
If a patient is considering a private specialist discussion, the useful question is not “does migraine qualify?”. It is whether their diagnosis, previous treatments, medicine use, headache pattern and risk profile mean they may qualify for a specialist assessment. The medical cannabis qualifying conditions guide can help with that first steer, but it is not the final clinical decision.
Previous treatment history usually matters. A specialist may want to know whether at least two relevant treatments have been tried, not tolerated, ineffective or unsuitable. For migraine, that might include acute medicines, anti-sickness medicines, preventive medicines, CGRP-pathway treatments, headache-clinic input or other approaches, depending on the person’s diagnosis and NHS/private care history.
Migraine and headache disorders need the right diagnosis
The NHS describes migraine as a common health condition that can cause a severe throbbing pain, usually on one side of the head, and can come with nausea, vomiting and sensitivity to light or sound. Some people have aura symptoms before or during an attack.
Headache disorders are not all the same. Migraine, cluster headache, tension-type headache, medication-overuse headache, post-traumatic headache, cervicogenic headache and headaches caused by another illness need different thinking. New, sudden, severe or unusual headaches may need urgent medical assessment rather than an online article.
That diagnostic boundary matters for medical cannabis content. An article should not treat all headaches as one category or imply that cannabis is a general headache tool. A prescriber would need to understand what type of headache is present and whether standard assessment or treatment has been completed.
What standard migraine care usually involves
NHS migraine guidance discusses acute treatment such as painkillers, triptans and anti-sickness medicines, and preventive treatment for people with frequent or severe migraine. Preventive options can include medicines such as beta blockers, antidepressants or anticonvulsants, and some patients may be referred for specialist treatments.
Those details matter because previous treatment history is part of many medical cannabis access discussions. A patient does not need to have tried every treatment. But a specialist usually needs to see that reasonable standard options have been considered, tried, not tolerated or unsuitable.
The Summary Care Record from your GP surgery is usually the practical first records step. If it shows migraine or headache diagnosis and relevant recent treatments, it may support an initial eligibility check. Extra neurology, headache-clinic or hospital letters can help if the SCR does not show enough detail.
For practical records guidance, read how to request your Summary Care Record and what counts as trying two treatments.
Why the evidence boundary is stricter for migraine
Some people report that cannabis or cannabinoids affect their headaches, sleep, nausea or anxiety. Patient experience can be real and still not be enough to support a treatment claim.
Migraine is a condition where outcomes can fluctuate, placebo effects can be large, and triggers, sleep, stress, hormones, medication use and other illnesses can change attack frequency. Research using non-standard products or self-reported outcomes does not translate neatly into UK prescribing guidance.
For this reason, this guide avoids claims that medical cannabis reduces migraine frequency, reduces attack severity, prevents attacks or treats headache disorders. Stronger evidence discussion should only be added from current systematic review evidence and checked clinically.
Medication-overuse and interaction risks
Headache medicine safety is not only about cannabis. People with frequent migraine may already use painkillers, triptans, anti-sickness medicines, preventive medicines, antidepressants, antiepileptic medicines, beta blockers, sleep medicines, supplements or non-prescribed cannabinoid products.
Medication-overuse headache is a known concern in headache care, where frequent use of acute treatments can make headaches worse or more persistent. This article does not claim cannabis causes medication-overuse headache in a specific way. It does mean any repeated use of symptom-relief products should be discussed honestly with a clinician.
The NHS medical cannabis page says CBD and THC can affect how other medicines work. That makes a complete medicine and supplement list essential. Interaction review is a normal specialist-prescribing and pharmacist-review step, not a reason to panic or self-manage medicine changes.
Safety screening may also cover:
- drowsiness, dizziness, concentration, falls risk and work safety;
- driving and impairment if THC is involved;
- anxiety, depression, psychosis, bipolar or mania risk, suicidality and previous adverse cannabis reactions;
- pregnancy, breastfeeding, cardiovascular, liver, kidney or substance-use concerns;
- whether headache symptoms suggest another condition needing separate review.
Do not stop, switch or reduce migraine or headache medicines without clinical advice.
What to ask a specialist
Useful questions include:
- What headache diagnosis are we working with, and is it clear enough for this assessment?
- Which standard migraine or headache treatments are most relevant in my history?
- Does my Summary Care Record show enough, or do you need neurology or headache-clinic letters?
- What is the evidence boundary for medical cannabis in my type of headache disorder?
- How would you assess medication-overuse risk?
- What interactions matter with my current acute and preventive medicines?
- What side effects, impairment or mental-health risks are most relevant for me?
- How would any treatment be reviewed, stopped or changed if it was not helping or was causing problems?
Patients can ask informed questions about forms such as oil, flower or extract if the consultation reaches that point. The prescriber decides suitability, product, dose, route and monitoring.
FAQ
Does migraine qualify for medical cannabis in the UK?
Not by diagnosis alone. Migraine or another headache disorder may be part of a specialist assessment, but access depends on diagnosis, previous treatments, current medicines, risk factors and clinical judgement.
Does medical cannabis treat migraine?
This article does not make that claim. The evidence is not strong enough here to present medical cannabis as a proven migraine treatment or preventive option.
Why is migraine different from a general pain article?
Migraine has specific acute and preventive treatments, and headache care has particular issues such as medication-overuse headache, triggers, aura, nausea and neurological red flags. It should not be reduced to generic pain.
What records are useful before an assessment?
Start with the Summary Care Record from your GP surgery. If it shows the diagnosis and relevant treatments, it may support an initial eligibility check. Neurology or headache-clinic letters can help where the SCR is too thin.
Can this article recommend a product or dose?
No. Product, form, dose, route, monitoring and suitability are prescriber decisions.
Sources
- NHS. Medical cannabis. https://www.nhs.uk/medicines/medical-cannabis/
- NICE. Cannabis-based medicinal products: recommendations, NG144. https://www.nice.org.uk/guidance/ng144/chapter/recommendations
- NHS. Migraine. https://www.nhs.uk/conditions/migraine/
- NHS England. Cannabis-based products for medicinal use. https://www.england.nhs.uk/long-read/cannabis-based-products-for-medicinal-use-cbpms/
- GMC. Information for doctors on cannabis-based products for medicinal use. https://www.gmc-uk.org/professional-standards/learning-materials/information-for-doctors-on-cannabis-based-products-for-medicinal-use
- CQC. Cannabis-based medicinal products: what CQC expects from providers. https://www.cqc.org.uk/guidance-providers/healthcare/cannabis-based-medicinal-products-what-cqc-expects-providers
- GOV.UK. Drug driving law. https://www.gov.uk/drug-driving-law
Cover image brief: cover-brief.md.
